BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33020591)

  • 1. Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
    Bazarbachi A; Labopin M; Blaise D; Forcade E; Socié G; Berceanu A; Angelucci E; Bulabois CE; Kröger N; Rambaldi A; Ceballos P; Mielke S; El Cheikh J; Yakoub-Agha I; Savani B; Spyridonidis A; Nagler A; Mohty M
    Bone Marrow Transplant; 2021 Mar; 56(3):622-634. PubMed ID: 33020591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
    Pagliardini T; Castagna L; Harbi S; Porta MD; Rey J; Fürst S; Bramanti S; Saillard C; Legrand F; Maisano V; Faucher C; Granata A; Hospital MA; Lining W; Weiller PJ; Calmels B; Charbonnier A; Lemarie C; Chabannon C; Vey N; Mokart D; Blaise D; Devillier R
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1803-1809. PubMed ID: 31128325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
    Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
    Sora F; Grazia CD; Chiusolo P; Raiola AM; Bregante S; Mordini N; Olivieri A; Iori AP; Patriarca F; Grisariu S; Terruzzi E; Rambaldi A; Sica S; Bruno B; Angelucci E; Bacigalupo A
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):698-703. PubMed ID: 31875522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
    Giannotti F; Labopin M; Shouval R; Sanz J; Arcese W; Angelucci E; Sierra J; Santasusana JR; Santarone S; Benedetto B; Rambaldi A; Saccardi R; Blaise D; Carella MA; Rocha V; Baron F; Mohty M; Ruggeri A; Nagler A
    J Hematol Oncol; 2018 Aug; 11(1):110. PubMed ID: 30165887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT.
    Swoboda R; Labopin M; Giebel S; Angelucci E; Arat M; Aljurf M; Sica S; Pavlu J; Socié G; Bernasconi P; Rigacci L; Tischer J; Risitano A; Rovira M; Saccardi R; Pioltelli P; Van Gorkom G; Vitek A; Savani BN; Spyridonidis A; Peric Z; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Mar; 57(3):399-406. PubMed ID: 35031709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
    J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
    J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.
    Saraceni F; Labopin M; Hamladji RM; Mufti G; Socié G; Shimoni A; Delage J; Deconinck E; Chevallier P; Blaise D; Sanz J; Huynh A; Forcade E; Savani BN; Mohty M; Nagler A;
    Oncotarget; 2018 Jan; 9(3):3379-3393. PubMed ID: 29423053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
    Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
    Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.
    Devillier R; Galimard JE; Labopin M; Blaise D; Raiola AM; Pavlu J; Castagna L; Socié G; Chalandon Y; Martino M; Stölzel F; Bug G; Bruno B; Vrhovac R; Charbonnier A; Olivieri A; Bay JO; Arroyo H; Yakoub-Agha I; Avenoso D; Neubauer A; Nguyen S; Forcade E; Brissot E; Savani B; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Sep; 57(9):1421-1427. PubMed ID: 35752739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
    El-Cheikh J; Labopin M; Al-Chami F; Bazarbachi A; Angelucci E; Santarone S; Bonifazi F; Carella AM; Castagna L; Bruno B; Iori AP; La Nasa G; Savani B; Nagler A; Mohty M
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):296-304. PubMed ID: 32081702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
    Santoro N; Labopin M; Giannotti F; Ehninger G; Niederwieser D; Brecht A; Stelljes M; Kröger N; Einsele H; Eder M; Hallek M; Glass B; Finke J; Ciceri F; Mohty M; Ruggeri A; Nagler A
    J Hematol Oncol; 2018 Apr; 11(1):55. PubMed ID: 29661208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
    Sanz J; Galimard JE; Labopin M; Afanasyev B; Angelucci E; Ciceri F; Blaise D; Cornelissen JJ; Meijer E; Diez-Martin JL; Koc Y; Rovira M; Castagna L; Savani B; Ruggeri A; Nagler A; Mohty M;
    J Hematol Oncol; 2020 May; 13(1):46. PubMed ID: 32375860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
    Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
    Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Ye Y; Labopin M; Gérard S; Yakoub-Agha I; Blau IW; Aljurf M; Forcade E; Gedde-Dahl T; Burns D; Vydra J; Halahleh K; Hamladji RM; Bazarbachi A; Nagler A; Brissot E; Li L; Luo Y; Zhao Y; Ciceri F; Huang H; Mohty M; Gorin NC
    Am J Hematol; 2024 Jul; 99(7):1290-1299. PubMed ID: 38654658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
    Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.